Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Niacin

Unchecked
From Pharmacopedia
Niacin (nicotinic acid, vitamin B3)
Niaspan (ER, Rx), Niacor (IR, Rx); huge OTC presence

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Pharmacy
Starting dose
Niaspan ER 500 mg PO at bedtime, titrate weekly to 1-2 g/d; flushing-protective aspirin 30-60 minutes before dose; pellagra replacement 100-500 mg/d
Preparations
OTC IR niacin 50-500 mg tablets; Niaspan ER 500, 750, 1000 mg tablets; "no-flush" niacin (inositol hexaniacinate, lacks evidence)
US FDA Max
2 g/d (Niaspan); higher off-label use historical
Common uses
Classification(s)
Pharmacology
Routes
Oral
Onset
Lipid changes 4-8 weeks
Duration
24 hours
Half-life
~1 hour (IR niacin); ER formulations extend functional duration[1]
Bioavailability
High (oral; food enhances)[1]
Pregnancy
Pharmacologic doses generally avoided in pregnancy; vitamin doses fine.[citation needed]
Legal status
OTC (low-dose, dietary supplement) and Rx-only (Niaspan ER) in US
Purported mechanism
Niacin in pharmacologic doses binds the GPR109A (HCA2) receptor on adipocytes, inhibiting hormone-sensitive lipase and decreasing free fatty acid release; the consequent reduction in hepatic substrate for VLDL synthesis lowers triglycerides and LDL, while a separate mechanism raises HDL.0 The AIM-HIGH (2011) and HPS2-THRIVE (2014) trials showed that adding niacin to statin therapy does not reduce cardiovascular events despite lipid changes, substantially reducing its modern use. Flushing (GPR109A-mediated PGD2 release in skin) is the universal adverse effect; aspirin pretreatment and ER formulations reduce but do not eliminate it[1].
Pharmacopedia is intended for reference. Nothing here is advice. In an emergency call 911; US Poison Control 1-800-222-1222. See the full disclaimer.

References

edit
  1. 1.0 1.1 1.2 FDA Prescribing Information, Niaspan (niacin ER), AbbVie, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020381s057lbl.pdf